• Explore /
  • Poster
  • / The inflamed immune phenotype (IIP): A clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across >16 primary tumor types.

The inflamed immune phenotype (IIP): A clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across >16 primary tumor types.

Abstract Poster

Authors

null

Jeanne Shen

Department of Pathology, Stanford University School of Medicine, Stanford, CA

Jeanne Shen , Yoon-La Choi , Taebum Lee , Hyojin Kim , Young Kwang Chae , Benjamin Dulken , Stephanie Bogdan , Maggie Huang , George A. Fisher Jr., Sehhoon Park , Se-Hoon Lee , Jun Eul Hwang , Jin-haeng Chung , Leeseul Kim , Seunghwan Shin , Yoojoo Lim , Heon Song , Sergio Pereira , Chan-Young Ock

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Tissue-Based Biomarkers

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2621)

DOI

10.1200/JCO.2022.40.16_suppl.2621

Abstract #

2621

Poster Bd #

276

Abstract Disclosures

Similar Posters

First Author: Biagio Ricciuti

First Author: Stephanie Leigh Alden

First Author: Hyojin Kim

First Author: Sehhoon Park